Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.

Angelopoulos N, Livadas S, Androulakis I, Petkova V, Rizoulis A, Boniakos A, Paparodis R, Tzoulis P, Mentzelopoulou V, Florakis D, Fousteris E, Korakovouni A and 5 more

Show all authors

Zianni D, Mouslech Z, Rizzo M, Mikhailidis DP, Anagnostis P

Journal of diabetes and its complications9 Oct 2025Cited by 2 (Europe PMC)

PMID41075711DOI10.1016/j.jdiacomp.2025.109181PepBankPUB-41075711

Publisher page PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, reductions in cholesterol, triglycerides, glucose, HbA1c and hepatic steatosis index were inversely associated with baseline levels.
In plain wordsIn adults with obesity without diabetes, people with higher starting values had larger falls in these measures on low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableAssociation of changes with baseline levels
Study
n = 75
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
and inversely associated with their baseline levels.
3 context sentences(design, population, supporting numbers)
Summary · context
TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels.
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571109
02HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, the HbA1c change with low-dose tirzepatide correlated with weight loss.
In plain wordsIn adults with obesity without diabetes, HbA1c change on low-dose tirzepatide was linked to how much weight people lost.
Peptide
Tirzepatide
Outcome
Not applicableHbA1c change correlated with weight loss
Study
n = 75
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
HbA1c and HSI changes correlated with weight loss
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571110
03HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, the hepatic steatosis index change with low-dose tirzepatide correlated with weight loss.
In plain wordsIn adults with obesity without diabetes, the fatty liver score change on low-dose tirzepatide was linked to how much weight people lost.
Peptide
Tirzepatide
Outcome
Not applicableHepatic steatosis index change correlated with weight loss
Study
n = 75
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
HbA1c and HSI changes correlated with weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571111
04HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, low-dose tirzepatide reduced body weight by 8.1% after 12 weeks.
In plain wordsIn adults with obesity without diabetes, body weight fell by 8.1% after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change at 12 weeks
Study
n = 75
Outcome group
Body weight · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Body weight change
−8.1%
12 weeks
Source sentences
Summary
After 12 weeks, body weight (-8.1 ± 4.3 %) and BMI significantly decreased
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571101
05HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, low-dose tirzepatide significantly reduced BMI after 12 weeks.
In plain wordsIn adults with obesity without diabetes, BMI fell after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseBMI change at 12 weeks
Study
n = 75
Outcome group
Body weight · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
After 12 weeks, body weight (-8.1 ± 4.3 %) and BMI significantly decreased
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571102
06HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, total cholesterol was significantly reduced after 12 weeks of low-dose tirzepatide.
In plain wordsIn adults with obesity without diabetes, total cholesterol fell after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseTotal cholesterol change
Study
n = 75
Outcome group
Lipids · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571103
07HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, LDL cholesterol was significantly reduced after 12 weeks of low-dose tirzepatide.
In plain wordsIn adults with obesity without diabetes, LDL cholesterol fell after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseLDL cholesterol change
Study
n = 75
Outcome group
Lipids · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571104
08HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, triglycerides were significantly reduced after 12 weeks of low-dose tirzepatide.
In plain wordsIn adults with obesity without diabetes, triglycerides fell after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseTriglycerides change
Study
n = 75
Outcome group
Lipids · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571105
09HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, fasting plasma glucose was significantly reduced after 12 weeks of low-dose tirzepatide.
In plain wordsIn adults with obesity without diabetes, fasting blood sugar fell after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseFasting plasma glucose change
Study
n = 75
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571106
10HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, HbA1c was significantly reduced after 12 weeks of low-dose tirzepatide.
In plain wordsIn adults with obesity without diabetes, HbA1c fell after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change
Study
n = 75
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571107
11HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, the hepatic steatosis index was significantly reduced after 12 weeks of low-dose tirzepatide.
In plain wordsIn adults with obesity without diabetes, a fatty liver score fell after 12 weeks of low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseHepatic steatosis index change
Study
n = 75
Outcome group
Liver fat and liver function · Liver
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571108
12HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, low-dose tirzepatide had no effect on HDL cholesterol.
In plain wordsIn adults with obesity without diabetes, low-dose tirzepatide did not change HDL cholesterol.
Peptide
Tirzepatide
Outcome
No significant changeHDL cholesterol change
Study
n = 75
Outcome group
Lipids · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
No effect was observed on HDL-C.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571112
13HumanObservational studyEfficacy outcome
In adults with obesity without diabetes, statin use had no impact on the outcomes of low-dose tirzepatide.
In plain wordsIn adults with obesity without diabetes, statin use did not change the results seen with low-dose tirzepatide.
Peptide
Tirzepatide
Outcome
No significant changeEffect of statin use on outcomes
Study
n = 75
Outcome group
Lipids · Metabolic and weight
Studied dose
2.5 mg/week, escalating to 5 mg/week · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Statin use had no impact on outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks.
Summary · context
Seventy-five participants (mean age 46.9 ± 9.9 years) were included.
Report a problemFND-4107571113

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.

Summary

Results from this study13

Version history

Subjects

Publication types

MeSH terms

Keywords